Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC regulates the antitumor immune response through CD47 and PD-L1

10 Mar 2016

Abstract excerpt

The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1). Suppression of MYC in mouse tumors and human tumor cells caused a reduction in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26966191
DOI: 10.1126/science.aac9935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC regulates the antitumor immune response through CD47 and PD-L1PMID 26966191Read ↗

MYC Overexpression Drives Immune Evasion in Human Cancer that is Reversible Through Restoration of Pro-Inflammatory MacrophagesSemantic proximity Read ↗

Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cellsSemantic proximity Read ↗

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read ↗

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.Semantic proximity Read ↗

Role of CD47 in tumor immunity: a potential target for combination therapySemantic proximity Read ↗

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read ↗

The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapySemantic proximity Read ↗

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor ImmunitySemantic proximity Read ↗

Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.Semantic proximity Read ↗

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read ↗

CD47 expression is critical for CAR T-cell survival in vivoSemantic proximity Read ↗

Absence of CD47 in the tumor microenvironment modulates tumor metabolism and immunosuppressive signatures limiting breast cancer progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.